Clinical Trials Logo
  1. Home
  2. HER2-positive Gastric Cancer
  3. NCT05586061

First-line Treatment With RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer — RCTS  

HER2-positive Gastric Cancer Clinical Trial

Official title:
A Prospective, Multicenter, Phase II Clinical Study of First-line Treatment for HER2 (Human Epidermal Growth Factor Receptor 2) Positive Advanced Gastric Cancer With Disitamab Vedotin in Combination With Tirelizumab and S-1

Clinical Trial Summary

This is a prospective, single arm, multicenter phase II study aimed at evaluating the efficacy and safety of Disitamab Vedotin in Combination With Tirelizumab and S-1 as first-line treatment for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05586061
Study type Interventional
Source Qilu Hospital of Shandong University
Contact Lian Liu, Doctor
Phone 0531-82169851
Email tounao@126.com
Status Not yet recruiting
Phase Phase 2
Start date November 1, 2022
Completion date December 31, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05070598 - Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer Phase 2
Active, not recruiting NCT04082364 - Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer Phase 2/Phase 3
Completed NCT03330561 - PRS-343 in HER2-Positive Solid Tumors Phase 1
Recruiting NCT05619016 - [68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors Phase 2
Active, not recruiting NCT05190445 - Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma Phase 2
Recruiting NCT05982834 - Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC Phase 1/Phase 2
Not yet recruiting NCT05313906 - RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer Phase 2
Recruiting NCT06328738 - ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer Phase 1
Recruiting NCT04319757 - ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors Phase 1
Recruiting NCT04520295 - ctDNA Screening in Advanced HER2 Positive Gastric Cancer
Withdrawn NCT04464967 - Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers Phase 1/Phase 2
Recruiting NCT06253650 - Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease Phase 2
Recruiting NCT05955833 - 89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study Phase 1
Not yet recruiting NCT06414733 - Vaccine Therapy in Treating Patients With Metastatic Solid Tumors Phase 1
Active, not recruiting NCT05555251 - BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors Phase 1/Phase 2
Withdrawn NCT04602117 - ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer Phase 1
Not yet recruiting NCT06439550 - Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC Phase 2
Recruiting NCT05514717 - A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 Phase 1
Terminated NCT05091528 - A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers Phase 1/Phase 2
Recruiting NCT05715931 - Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma Phase 2